Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters

[1]  G. Rossi,et al.  Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. , 2008, The Journal of antimicrobial chemotherapy.

[2]  P. Koistinen,et al.  Influence of chemotherapy courses on the rate of bloodstream infections during neutropenia in adult acute myeloid leukaemia , 2008, Scandinavian journal of infectious diseases.

[3]  L. Baden,et al.  Antibiotic prophylaxis for patients with acute leukemia , 2008, Leukemia & lymphoma.

[4]  M. Paesmans,et al.  Bacteraemia in febrile neutropenic cancer patients. , 2007, International journal of antimicrobial agents.

[5]  Lucinda J Billingham,et al.  Rational selection of patients for antibacterial prophylaxis after chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Bodey,et al.  Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  S. Homan,et al.  APPLIED MIXED MODELS IN MEDICINE, 2ND ED. , 2007 .

[8]  E. Jantunen,et al.  Long‐term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML‐92 study by the Finnish Leukaemia Group , 2007, European journal of haematology.

[9]  J. Stockman.  Antibacterial Prophylaxis After Chemotherapy for Solid Tumors and Lymphomas , 2007 .

[10]  J. Szer,et al.  A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Robin J. Prescott,et al.  Applied Mixed Models in Medicine: Brown/Applied Mixed Models in Medicine, 2nd Edition , 2006 .

[12]  H. Goldschmidt,et al.  Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial , 2006, Bone Marrow Transplantation.

[13]  V. Gonçalves,et al.  Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[14]  R. Foà,et al.  Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. , 2005, The New England journal of medicine.

[15]  R. Huddart,et al.  Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. , 2005, The New England journal of medicine.

[16]  L. Baden.  Prophylactic antimicrobial agents and the importance of fitness. , 2005, The New England journal of medicine.

[17]  W. Kern,et al.  Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis , 1989, Infection.

[18]  J. Donnelly,et al.  Measuring mucosal damage induced by cytotoxic therapy , 2004, Supportive Care in Cancer.

[19]  R. Wenzel,et al.  Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  V. Gonçalves,et al.  Prospective Evaluation of the Epidemiology, Microbiology, and Outcome of Bloodstream Infections in Hematologic Patients in a Single Cancer Center , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  R. Leclercq,et al.  Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  角田 明良,et al.  結腸癌術後の早期離床・早期経口摂取に関するProspective Randomized Trial , 2002 .

[23]  Wilhelm Busch,et al.  Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever , 2000, Antimicrobial Agents and Chemotherapy.

[24]  T. Madani.  Clinical Infections and Bloodstream Isolates Associated with Fever in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia , 2000, Infection.

[25]  Helen Brown,et al.  Applied Mixed Models in Medicine , 2000, Technometrics.

[26]  J. L. Fuentes-Allen,et al.  Microbiological findings in febrile neutropenia. , 2000, Archives of medical research.

[27]  S. Zinner.  Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  A. Wåhlin,et al.  Intestinal permeability in patients with acute myeloid leukemia , 1998, European journal of haematology.

[30]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  P. Kujala,et al.  Continuous-monitoring blood culture screening system improves the detection of bacteremia in neutropenic patients. , 1996, Scandinavian journal of infectious diseases.

[32]  M. Paesmans,et al.  Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer , 1995, Antimicrobial agents and chemotherapy.

[33]  P. Francioli,et al.  Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[35]  L. Young,et al.  GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever , 1997 .

[36]  J. Shenep,et al.  Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1991, The Journal of infectious diseases.

[37]  L. Young,et al.  From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1990, The Journal of infectious diseases.

[38]  H. Dupont.  Secretary's Office , 1987 .

[39]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[40]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[41]  W Satterlee,et al.  Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. , 1971, The New England journal of medicine.

[42]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.

[43]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.